Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'

Aron M. Levin, Darren L. Bates, Aaron M. Ring, Carsten Krieg, Jack T. Lin, Leon Su, Ignacio Moraga, Miro E. Raeber, Gregory R. Bowman, Paul Novick, Vijay S. Pande, C. Garrison Fathman, Onur Boyman, K. Christopher Garcia

Research output: Contribution to journalArticlepeer-review

442 Scopus citations

Abstract

The immunostimulatory cytokine interleukin-2 (IL-2) is a growth factor for a wide range of leukocytes, including T cells and natural killer (NK) cells. Considerable effort has been invested in using IL-2 as a therapeutic agent for a variety of immune disorders ranging from AIDS to cancer. However, adverse effects have limited its use in the clinic. On activated T cells, IL-2 signals through a quaternary 'high affinity' receptor complex consisting of IL-2, IL-2Rα (termed CD25), IL-2Rβ and IL-2Rγ. Naive T cells express only a low density of IL-2Rβ and IL-2Rγ, and are therefore relatively insensitive to IL-2, but acquire sensitivity after CD25 expression, which captures the cytokine and presents it to IL-2Rβ and IL-2Rγ. Here, using in vitro evolution, we eliminated the functional requirement of IL-2 for CD25 expression by engineering an IL-2 'superkine' (also called super-2) with increased binding affinity for IL-2Rβ. Crystal structures of the IL-2 superkine in free and receptor-bound forms showed that the evolved mutations are principally in the core of the cytokine, and molecular dynamics simulations indicated that the evolved mutations stabilized IL-2, reducing the flexibility of a helix in the IL-2Rβ binding site, into an optimized receptor-binding conformation resembling that when bound to CD25. The evolved mutations in the IL-2 superkine recapitulated the functional role of CD25 by eliciting potent phosphorylation of STAT5 and vigorous proliferation of T cells irrespective of CD25 expression. Compared to IL-2, the IL-2 superkine induced superior expansion of cytotoxic T cells, leading to improved antitumour responses in vivo, and elicited proportionally less expansion of T regulatory cells and reduced pulmonary oedema. Collectively, we show that in vitro evolution has mimicked the functional role of CD25 in enhancing IL-2 potency and regulating target cell specificity, which has implications for immunotherapy.

Original languageEnglish
Pages (from-to)529-533
Number of pages5
JournalNature
Volume484
Issue number7395
DOIs
StatePublished - Apr 26 2012

Fingerprint

Dive into the research topics of 'Exploiting a natural conformational switch to engineer an interleukin-2 'superkine''. Together they form a unique fingerprint.

Cite this